Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence

Objective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice. Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31, 2025. It was based on a retrospective analysis of real clinical practice data. Information on patients was collected and analyzed at baseline and after 1, 6, and 12 months of treatment. Results and discussion. A total of 1,576 patients (81.7% women) with RA, aged 55.0 [44.0; 63.0] years and with RA duration of 100.0 [50.0; 156.0] months, were included in the program. After 6 and 12 months of OKZ therapy, the treatment target (remission/low activity) was achieved in 63.3% and 79.8% of patients by DAS28-CRP, and in 55.4% and 75.5% by CDAI respectively. Gender, age, seropositivity, and use of biologic disease-modifying antirheumatic drugs did not significantly affect the achievement of the treatment goal. During the observation period, a significant proportion of patients were able to discontinue glucocorticoids (GCs): 51.1% of patients received GCs initially, after 6 months, 27.6% of patients still received GCs, and after 12 months, 17.0%. During the observation, OKZ treatment was discontinued in 148 (9.5%) patients: in 50 (3.2%) patients due to insufficient efficacy, in 63 (4.0%) patients due to adverse events, and in 35 (2.2%) patients due to other reasons. Conclusion. IL-6 inhibition with OKZ is both effective and safe for achieving RA therapy goals in real-world clinical settings.

Authors

Institutions

Publication Details

Journal
Modern Rheumatology Journal
Published
2025-04-22
DOI
https://doi.org/10.14412/1996-7012-2025-2-39-49
Citations
2
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
3.34
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence

Е. С. Алексеев, А. М. Лила, S. Yu. Davidyan, A. V. Makevnina et al.
2 citations
Modern Rheumatology Journal
Rheumatoid Arthritis Research and Therapies
3.34
article

Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence

Е. С. Алексеев, А. М. Лила, S. Yu. Davidyan, A. V. Makevnina, A. V. Fedorova, I. B. Vinogradova, Андрей Владимирович Рыбин, Alena I. Zagrebneva, L. V. Ivanova, L. V. Solodovnikova, S. A. Bykova, E. V. Zemerova, A. Pavlova, I. G. Bannikova, T. S. Salnikova, L. V. Belozertseva, O. E. Epifanova, P. А. Shesternya, M. V. Zlobin, E. Klyuchnikova, Е. А. Богданова, О. В. Антипова, E. Vasilenko, S. P. Yakupova, E. R. Myasoutova, T. V. Plaksina, N. A. Ilyina, E. V. Jakovleva, L. V. Ilyushina, E. E. Nakonechnaya, I. A. Cherencova, Yu. V. Arbuzova
article en
2 citations

Abstract

Objective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice. Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31, 2025. It was based on a retrospective analysis of real clinical practice data. Information on patients was collected and analyzed at baseline and after 1, 6, and 12 months of treatment. Results and discussion. A total of 1,576 patients (81.7% women) with RA, aged 55.0 [44.0; 63.0] years and with RA duration of 100.0 [50.0; 156.0] months, were included in the program. After 6 and 12 months of OKZ therapy, the treatment target (remission/low activity) was achieved in 63.3% and 79.8% of patients by DAS28-CRP, and in 55.4% and 75.5% by CDAI respectively. Gender, age, seropositivity, and use of biologic disease-modifying antirheumatic drugs did not significantly affect the achievement of the treatment goal. During the observation period, a significant proportion of patients were able to discontinue glucocorticoids (GCs): 51.1% of patients received GCs initially, after 6 months, 27.6% of patients still received GCs, and after 12 months, 17.0%. During the observation, OKZ treatment was discontinued in 148 (9.5%) patients: in 50 (3.2%) patients due to insufficient efficacy, in 63 (4.0%) patients due to adverse events, and in 35 (2.2%) patients due to other reasons. Conclusion. IL-6 inhibition with OKZ is both effective and safe for achieving RA therapy goals in real-world clinical settings.

Modern Rheumatology JournalVol. 19(2)
Russian Academy of Sciences (RU), Kazan State Medical University (RU), Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan (RU), Krasnoyarsk State Medical University (RU), Nizhny Novgorod Regional Clinical Hospital named after Semashko (RU), Regional Clinical Hospital No 4 (RU), Ulyanovsk Regional Clinical Hospital (RU), R-Pharm (Russia) (RU), Research Institute of Fundamental and Clinical Immunology (RU), National Medical and Surgical Center named after N.I. Pirogov (RU), Institute of Cytology and Genetics (RU), Ministry of Health of the Russian Federation (RU), Association of Rheumatologists of Russia (RU), Ivanovo State Medical Academy (RU), City Clinical Hospital (RU), Central Clinical Hospital (PL), Regional Clinical Research (US), Specialized Clinical Psychiatric Hospital No. 1 (RU), Tula Regional Clinical Hospital (RU), Institute of Clinical and Experimental Lymphology (RU)
Openalex Percentile: Top 9%
Rheumatoid Arthritis Research and Therapies
3.34
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.